NCT06073821 2026-04-16
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
34 trialsNCT04269902 2026-04-15
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT06943872 2026-04-15
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT03462719 2026-04-13
GLOW
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT03701282 2026-04-13
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03737981 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06428019 2026-04-09
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT04408638 2026-04-07
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06084936 2026-04-02
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT05100862 2026-03-18
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT04285567 2026-03-03
CRISTALLO
Hoffmann-La Roche
Phase 3 Completed
NCT05057494 2026-02-18
MAJIC
AstraZeneca
Phase 3 Active not recruiting
NCT05929222 2025-12-24
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3 Recruiting
NCT02242942 2025-11-06
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT02475681 2025-08-27
ElevateTN
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05197192 2025-08-17
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group
Phase 3 Recruiting
NCT04608318 2024-12-31
CLL17
German CLL Study Group
Phase 3 Active not recruiting
NCT02950051 2024-12-30
GAIA
German CLL Study Group
Phase 3 Completed
NCT03836261 2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3 Active not recruiting
NCT02612311 2024-12-13
UNITY-CLL
TG Therapeutics, Inc.
Phase 3 Terminated
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT03406156 2024-08-06
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
AbbVie
Phase 3 Completed
NCT01332968 2022-08-11
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
Hoffmann-La Roche
Phase 3 Completed
NCT04796922 2022-07-18
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Incyte Corporation
Phase 3 Withdrawn
NCT02264574 2020-09-21
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Pharmacyclics LLC.
Phase 3 Completed
NCT01059630 2020-01-13
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)
Genentech, Inc.
Phase 3 Completed
NCT01905943 2019-10-28
A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Phase 3 Completed
NCT01287741 2019-04-12
A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)
Hoffmann-La Roche
Phase 3 Terminated
NCT01980875 2018-11-19
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Gilead Sciences
Phase 3 Terminated
NCT01010061 2018-09-14
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)
Hoffmann-La Roche
Phase 3 Completed
NCT01998880 2018-09-14
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
Hoffmann-La Roche
Phase 3 Completed
NCT02053610 2018-09-14
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Hoffmann-La Roche
Phase 3 Completed
NCT01659099 2018-03-07
GAINED
The Lymphoma Academic Research Organisation
Phase 3 Terminated